PMC:7212965 / 35713-36612 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T75","span":{"begin":147,"end":155},"obj":"Body_part"},{"id":"T76","span":{"begin":292,"end":297},"obj":"Body_part"},{"id":"T77","span":{"begin":475,"end":480},"obj":"Body_part"}],"attributes":[{"id":"A75","pred":"fma_id","subj":"T75","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A76","pred":"fma_id","subj":"T76","obj":"http://purl.org/sig/ont/fma/fma7197"},{"id":"A77","pred":"fma_id","subj":"T77","obj":"http://purl.org/sig/ont/fma/fma7197"}],"text":"The available studies suggest that abnormal LFTs are more commonly attributable to secondary effects (eg, systemic inflammatory response syndrome, cytokine storm, ischemic hepatitis/shock, sepsis, and drug hepatotoxicity) than primary virus-mediated hepatocellular injury.7 , 9 , 80 However, liver histopathology from patients with COVID-19 have revealed mild lobular and portal inflammation and microvesicular steatosis suggestive of either virally mediated or drug-induced liver injury.81 In addition, some studies have revealed that abnormal LFTs at hospital admission may be associated with a higher risk for severe COVID-19 (odds ratio, 2.73; 95% CI, 1.19–6.3).9 Therefore, we advise checking baseline LFTs in all patients on admission and monitoring of LFTs throughout the hospitalization, particularly in patients undergoing drug therapy for COVID-19 associated with potential hepatotoxicity."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T58","span":{"begin":292,"end":297},"obj":"Body_part"},{"id":"T59","span":{"begin":475,"end":480},"obj":"Body_part"}],"attributes":[{"id":"A58","pred":"uberon_id","subj":"T58","obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"A59","pred":"uberon_id","subj":"T59","obj":"http://purl.obolibrary.org/obo/UBERON_0002107"}],"text":"The available studies suggest that abnormal LFTs are more commonly attributable to secondary effects (eg, systemic inflammatory response syndrome, cytokine storm, ischemic hepatitis/shock, sepsis, and drug hepatotoxicity) than primary virus-mediated hepatocellular injury.7 , 9 , 80 However, liver histopathology from patients with COVID-19 have revealed mild lobular and portal inflammation and microvesicular steatosis suggestive of either virally mediated or drug-induced liver injury.81 In addition, some studies have revealed that abnormal LFTs at hospital admission may be associated with a higher risk for severe COVID-19 (odds ratio, 2.73; 95% CI, 1.19–6.3).9 Therefore, we advise checking baseline LFTs in all patients on admission and monitoring of LFTs throughout the hospitalization, particularly in patients undergoing drug therapy for COVID-19 associated with potential hepatotoxicity."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T164","span":{"begin":172,"end":181},"obj":"Disease"},{"id":"T165","span":{"begin":265,"end":271},"obj":"Disease"},{"id":"T166","span":{"begin":332,"end":340},"obj":"Disease"},{"id":"T167","span":{"begin":379,"end":391},"obj":"Disease"},{"id":"T168","span":{"begin":462,"end":487},"obj":"Disease"},{"id":"T169","span":{"begin":481,"end":487},"obj":"Disease"},{"id":"T170","span":{"begin":620,"end":628},"obj":"Disease"},{"id":"T171","span":{"begin":849,"end":857},"obj":"Disease"}],"attributes":[{"id":"A164","pred":"mondo_id","subj":"T164","obj":"http://purl.obolibrary.org/obo/MONDO_0002251"},{"id":"A165","pred":"mondo_id","subj":"T165","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"},{"id":"A166","pred":"mondo_id","subj":"T166","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A167","pred":"mondo_id","subj":"T167","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"},{"id":"A168","pred":"mondo_id","subj":"T168","obj":"http://purl.obolibrary.org/obo/MONDO_0005359"},{"id":"A169","pred":"mondo_id","subj":"T169","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"},{"id":"A170","pred":"mondo_id","subj":"T170","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A171","pred":"mondo_id","subj":"T171","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"The available studies suggest that abnormal LFTs are more commonly attributable to secondary effects (eg, systemic inflammatory response syndrome, cytokine storm, ischemic hepatitis/shock, sepsis, and drug hepatotoxicity) than primary virus-mediated hepatocellular injury.7 , 9 , 80 However, liver histopathology from patients with COVID-19 have revealed mild lobular and portal inflammation and microvesicular steatosis suggestive of either virally mediated or drug-induced liver injury.81 In addition, some studies have revealed that abnormal LFTs at hospital admission may be associated with a higher risk for severe COVID-19 (odds ratio, 2.73; 95% CI, 1.19–6.3).9 Therefore, we advise checking baseline LFTs in all patients on admission and monitoring of LFTs throughout the hospitalization, particularly in patients undergoing drug therapy for COVID-19 associated with potential hepatotoxicity."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T281","span":{"begin":235,"end":240},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T282","span":{"begin":292,"end":297},"obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"T283","span":{"begin":292,"end":297},"obj":"http://www.ebi.ac.uk/efo/EFO_0000887"},{"id":"T284","span":{"begin":475,"end":480},"obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"T285","span":{"begin":475,"end":480},"obj":"http://www.ebi.ac.uk/efo/EFO_0000887"},{"id":"T286","span":{"begin":595,"end":596},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"The available studies suggest that abnormal LFTs are more commonly attributable to secondary effects (eg, systemic inflammatory response syndrome, cytokine storm, ischemic hepatitis/shock, sepsis, and drug hepatotoxicity) than primary virus-mediated hepatocellular injury.7 , 9 , 80 However, liver histopathology from patients with COVID-19 have revealed mild lobular and portal inflammation and microvesicular steatosis suggestive of either virally mediated or drug-induced liver injury.81 In addition, some studies have revealed that abnormal LFTs at hospital admission may be associated with a higher risk for severe COVID-19 (odds ratio, 2.73; 95% CI, 1.19–6.3).9 Therefore, we advise checking baseline LFTs in all patients on admission and monitoring of LFTs throughout the hospitalization, particularly in patients undergoing drug therapy for COVID-19 associated with potential hepatotoxicity."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T54","span":{"begin":201,"end":205},"obj":"Chemical"},{"id":"T55","span":{"begin":462,"end":466},"obj":"Chemical"},{"id":"T56","span":{"begin":832,"end":836},"obj":"Chemical"}],"attributes":[{"id":"A54","pred":"chebi_id","subj":"T54","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A55","pred":"chebi_id","subj":"T55","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A56","pred":"chebi_id","subj":"T56","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"The available studies suggest that abnormal LFTs are more commonly attributable to secondary effects (eg, systemic inflammatory response syndrome, cytokine storm, ischemic hepatitis/shock, sepsis, and drug hepatotoxicity) than primary virus-mediated hepatocellular injury.7 , 9 , 80 However, liver histopathology from patients with COVID-19 have revealed mild lobular and portal inflammation and microvesicular steatosis suggestive of either virally mediated or drug-induced liver injury.81 In addition, some studies have revealed that abnormal LFTs at hospital admission may be associated with a higher risk for severe COVID-19 (odds ratio, 2.73; 95% CI, 1.19–6.3).9 Therefore, we advise checking baseline LFTs in all patients on admission and monitoring of LFTs throughout the hospitalization, particularly in patients undergoing drug therapy for COVID-19 associated with potential hepatotoxicity."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T159","span":{"begin":147,"end":161},"obj":"Phenotype"},{"id":"T160","span":{"begin":172,"end":181},"obj":"Phenotype"},{"id":"T161","span":{"begin":182,"end":187},"obj":"Phenotype"},{"id":"T162","span":{"begin":189,"end":195},"obj":"Phenotype"},{"id":"T163","span":{"begin":372,"end":391},"obj":"Phenotype"},{"id":"T164","span":{"begin":396,"end":420},"obj":"Phenotype"}],"attributes":[{"id":"A159","pred":"hp_id","subj":"T159","obj":"http://purl.obolibrary.org/obo/HP_0033041"},{"id":"A160","pred":"hp_id","subj":"T160","obj":"http://purl.obolibrary.org/obo/HP_0012115"},{"id":"A161","pred":"hp_id","subj":"T161","obj":"http://purl.obolibrary.org/obo/HP_0031273"},{"id":"A162","pred":"hp_id","subj":"T162","obj":"http://purl.obolibrary.org/obo/HP_0100806"},{"id":"A163","pred":"hp_id","subj":"T163","obj":"http://purl.obolibrary.org/obo/HP_0033196"},{"id":"A164","pred":"hp_id","subj":"T164","obj":"http://purl.obolibrary.org/obo/HP_0001414"}],"text":"The available studies suggest that abnormal LFTs are more commonly attributable to secondary effects (eg, systemic inflammatory response syndrome, cytokine storm, ischemic hepatitis/shock, sepsis, and drug hepatotoxicity) than primary virus-mediated hepatocellular injury.7 , 9 , 80 However, liver histopathology from patients with COVID-19 have revealed mild lobular and portal inflammation and microvesicular steatosis suggestive of either virally mediated or drug-induced liver injury.81 In addition, some studies have revealed that abnormal LFTs at hospital admission may be associated with a higher risk for severe COVID-19 (odds ratio, 2.73; 95% CI, 1.19–6.3).9 Therefore, we advise checking baseline LFTs in all patients on admission and monitoring of LFTs throughout the hospitalization, particularly in patients undergoing drug therapy for COVID-19 associated with potential hepatotoxicity."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T7","span":{"begin":115,"end":136},"obj":"http://purl.obolibrary.org/obo/GO_0006954"},{"id":"T8","span":{"begin":379,"end":391},"obj":"http://purl.obolibrary.org/obo/GO_0006954"}],"text":"The available studies suggest that abnormal LFTs are more commonly attributable to secondary effects (eg, systemic inflammatory response syndrome, cytokine storm, ischemic hepatitis/shock, sepsis, and drug hepatotoxicity) than primary virus-mediated hepatocellular injury.7 , 9 , 80 However, liver histopathology from patients with COVID-19 have revealed mild lobular and portal inflammation and microvesicular steatosis suggestive of either virally mediated or drug-induced liver injury.81 In addition, some studies have revealed that abnormal LFTs at hospital admission may be associated with a higher risk for severe COVID-19 (odds ratio, 2.73; 95% CI, 1.19–6.3).9 Therefore, we advise checking baseline LFTs in all patients on admission and monitoring of LFTs throughout the hospitalization, particularly in patients undergoing drug therapy for COVID-19 associated with potential hepatotoxicity."}

{"project":"2_test","denotations":[{"id":"32407808-32145190-43469306","span":{"begin":272,"end":273},"obj":"32145190"},{"id":"32407808-32085846-43469307","span":{"begin":488,"end":490},"obj":"32085846"}],"text":"The available studies suggest that abnormal LFTs are more commonly attributable to secondary effects (eg, systemic inflammatory response syndrome, cytokine storm, ischemic hepatitis/shock, sepsis, and drug hepatotoxicity) than primary virus-mediated hepatocellular injury.7 , 9 , 80 However, liver histopathology from patients with COVID-19 have revealed mild lobular and portal inflammation and microvesicular steatosis suggestive of either virally mediated or drug-induced liver injury.81 In addition, some studies have revealed that abnormal LFTs at hospital admission may be associated with a higher risk for severe COVID-19 (odds ratio, 2.73; 95% CI, 1.19–6.3).9 Therefore, we advise checking baseline LFTs in all patients on admission and monitoring of LFTs throughout the hospitalization, particularly in patients undergoing drug therapy for COVID-19 associated with potential hepatotoxicity."}

{"project":"LitCovid-sentences","denotations":[{"id":"T227","span":{"begin":0,"end":899},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The available studies suggest that abnormal LFTs are more commonly attributable to secondary effects (eg, systemic inflammatory response syndrome, cytokine storm, ischemic hepatitis/shock, sepsis, and drug hepatotoxicity) than primary virus-mediated hepatocellular injury.7 , 9 , 80 However, liver histopathology from patients with COVID-19 have revealed mild lobular and portal inflammation and microvesicular steatosis suggestive of either virally mediated or drug-induced liver injury.81 In addition, some studies have revealed that abnormal LFTs at hospital admission may be associated with a higher risk for severe COVID-19 (odds ratio, 2.73; 95% CI, 1.19–6.3).9 Therefore, we advise checking baseline LFTs in all patients on admission and monitoring of LFTs throughout the hospitalization, particularly in patients undergoing drug therapy for COVID-19 associated with potential hepatotoxicity."}

{"project":"LitCovid-PubTator","denotations":[{"id":"895","span":{"begin":318,"end":326},"obj":"Species"},{"id":"896","span":{"begin":719,"end":727},"obj":"Species"},{"id":"897","span":{"begin":812,"end":820},"obj":"Species"},{"id":"907","span":{"begin":163,"end":187},"obj":"Disease"},{"id":"908","span":{"begin":189,"end":195},"obj":"Disease"},{"id":"909","span":{"begin":201,"end":220},"obj":"Disease"},{"id":"910","span":{"begin":250,"end":271},"obj":"Disease"},{"id":"911","span":{"begin":332,"end":340},"obj":"Disease"},{"id":"912","span":{"begin":379,"end":391},"obj":"Disease"},{"id":"913","span":{"begin":396,"end":420},"obj":"Disease"},{"id":"914","span":{"begin":475,"end":487},"obj":"Disease"},{"id":"915","span":{"begin":536,"end":549},"obj":"Disease"},{"id":"916","span":{"begin":620,"end":628},"obj":"Disease"},{"id":"917","span":{"begin":849,"end":857},"obj":"Disease"},{"id":"918","span":{"begin":884,"end":898},"obj":"Disease"}],"attributes":[{"id":"A895","pred":"tao:has_database_id","subj":"895","obj":"Tax:9606"},{"id":"A896","pred":"tao:has_database_id","subj":"896","obj":"Tax:9606"},{"id":"A897","pred":"tao:has_database_id","subj":"897","obj":"Tax:9606"},{"id":"A907","pred":"tao:has_database_id","subj":"907","obj":"MESH:D012772"},{"id":"A908","pred":"tao:has_database_id","subj":"908","obj":"MESH:D018805"},{"id":"A909","pred":"tao:has_database_id","subj":"909","obj":"MESH:D056486"},{"id":"A910","pred":"tao:has_database_id","subj":"910","obj":"MESH:D056486"},{"id":"A911","pred":"tao:has_database_id","subj":"911","obj":"MESH:C000657245"},{"id":"A912","pred":"tao:has_database_id","subj":"912","obj":"MESH:D007249"},{"id":"A913","pred":"tao:has_database_id","subj":"913","obj":"MESH:D005234"},{"id":"A914","pred":"tao:has_database_id","subj":"914","obj":"MESH:D017093"},{"id":"A915","pred":"tao:has_database_id","subj":"915","obj":"MESH:D018376"},{"id":"A916","pred":"tao:has_database_id","subj":"916","obj":"MESH:C000657245"},{"id":"A917","pred":"tao:has_database_id","subj":"917","obj":"MESH:C000657245"},{"id":"A918","pred":"tao:has_database_id","subj":"918","obj":"MESH:D056486"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The available studies suggest that abnormal LFTs are more commonly attributable to secondary effects (eg, systemic inflammatory response syndrome, cytokine storm, ischemic hepatitis/shock, sepsis, and drug hepatotoxicity) than primary virus-mediated hepatocellular injury.7 , 9 , 80 However, liver histopathology from patients with COVID-19 have revealed mild lobular and portal inflammation and microvesicular steatosis suggestive of either virally mediated or drug-induced liver injury.81 In addition, some studies have revealed that abnormal LFTs at hospital admission may be associated with a higher risk for severe COVID-19 (odds ratio, 2.73; 95% CI, 1.19–6.3).9 Therefore, we advise checking baseline LFTs in all patients on admission and monitoring of LFTs throughout the hospitalization, particularly in patients undergoing drug therapy for COVID-19 associated with potential hepatotoxicity."}